evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

29 questions · 29 findings · 17 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2 · 6.9%GRADE not reported 0 · 0%Very low 6 · 20.7%Low 8 · 27.6%Moderate 10 · 34.5%High 3 · 10.3%

Sunitinib vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.

Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with nivolumab + ipilimumab (targeted agent versus combinations of… (moderate certainty).

1 finding from 1 review

160/4.5 mcg BDF single inhaler therapy vs current best practice

Fatal serious adverse events · adults with asthma not well controlled on ICS

160/4.5 mcg BDF single inhaler therapy showed no clear difference in fatal serious adverse events compared with current best practice (low certainty).

1 finding from 1 review

160/4.5 mcg BDF single inhaler therapy vs current best practice

Non‐fatal serious adverse events · adults with asthma not well controlled on ICS

160/4.5 mcg BDF single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with current best practice (low certainty).

1 finding from 1 review

SiT for maintenance/relief vs higher‐dose ICS/LABA + SABA

Patients with serious adverse events · Studies recruited adults and adolescents aged 12 and older with chronic asthma

SiT for maintenance/relief showed no clear difference in patients with serious adverse events compared with higher‐dose ICS/LABA + SABA (moderate certainty).

1 finding from 1 review